20 clinical sites and 150 patients is a very large clinical trial and this will provide us with sufficient data, which if successful we should see a further paradigm shift of BTM becoming the standard of care as clinicians move away from biological matrices due to our superior effectiveness and safety.
Very exciting few years ahead for this company with such a bright future on a global scale.
Ann: USA FDA approves Pivotal Trial IDE, page-27
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
-0.050(2.02%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.45 | $2.35 | $3.794M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2112 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.42 | 27096 | 4 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |